We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
ACC.24 - Results of the Balance trial showed that the APOC3 ASO olezarsen reduces triglycerides in patients with familial chylomicronemia syndrome (FCS). The data of the secondary outcome of new-onset pancreatitis were quite astonishing, according to Erik Stroes.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of Balance were simultaneously published in N Engl J Med.
Release date: 10 april 2024
ACC.24 - Results of the Balance trial showed that the APOC3 ASO olezarsen reduces triglycerides in patients with familial chylomicronemia syndrome (FCS). The data of the secondary outcome of new-onset pancreatitis were quite astonishing, according to Erik Stroes.
This video was recorded in response to a presentation at the Congress of the American College of Cardiology (ACC) 2024.
Erik Stroes, MD, PhD is professor of Vascular Medicine at Amsterdam University Medical Center in Amsterdam, The Netherlands.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of Balance were simultaneously published in N Engl J Med.
Release date: 10 april 2024
Stay current with the best on medical education
